Long-term graft outcome is not necessarily affected by delayed onset of graft function and early acute rejection

Transplantation

Volumn 64, Issue 1, 1997, Pages 103-107

  Lehtonen, Satu R K ^a   Isoniemi, Helena M ^a   Salmela, Kaija T ^a   Taskinen, Eero I ^a   Vwillebrand, Eeva O ^a   Ahonen, Juhani P ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ADULT; ARTICLE; CADAVER KIDNEY; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR;

ACUTE DISEASE; ADULT; AZATHIOPRINE; CHRONIC DISEASE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HALF-LIFE; HUMANS; KIDNEY TRANSPLANTATION; METHYLPREDNISOLONE; MIDDLE AGED; REOPERATION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0342871970     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707150-00019     Document Type: Article

References (23)

1. Yilmaz S, Häyry P. The impact of acute episodes of rejection on the generation of chronic rejection in rat renal allografts. Transplantation 1993; 56: 1153.
2. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857.
3. Tesi RJ, Elkhammas EA, Henry ML, Davies EA, Salazar A, Ferguson RM. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Transplant Proc 1993; 25: 901.
4. Almond PS, Matas AJ, Gillingham KJ, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
5. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
6. Gulanikar AC, MacDonald AS, Sugurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53: 323.
7. Isoniemi H, Kyllönen L, Eklund B, et al. Acute rejection under triple immunosuppressive therapy does not increase the risk of late first cadaveric renal allograft loss. Transplant Proc 1995; 27: 875.
8. Isoniemi H, Lehtonen S, Salmela K, Ahonen J. Does delayed kidney graft function increase the risk of chronic rejection? Transpl Int 1996; 9: S5.
9. Halloran PF, Aprile MA, Farewell V, et al. Early function as the principal correlate of graft survival. Transplantation 1988; 46: 223.
10. Miwa H, vanLoenen M, Vanderwerf BA. The long-term effect of delayed graft function on cadaveric renal transplants treated with low dose cyclosporine. In: Terasaki P, ed. Clinical transplants 1989. Los Angeles: UCLA Tissue Typing laboratory, 275.
11. Sanfilippo F, Vaughn WK, Spees EK, Lucas BA. The effects of delayed graft function on renal transplantation. Transplant Proc 1985; 18: 13.
12. Troppmann C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. Transplantation 1995; 59: 962.
13. Feldman HI, Grayer R, Berlin JA, et al. Delayed function reduces renal allograft survival independent of acute rejection. Nephrol Dial Transplant 1996; 11: 1306.
14. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56: 307.
15. Ferguson R. Acute rejection episodes - best predictor of long term primary cadaveric renal transplant survival. Clin Transplant 1994; 8: 328.
16. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary renal allograft recipients. Transplantation 1995; 60: 225.
17. The European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
18. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Why cyclosporine (CsA) prevents acute rejection (AREJ) without preventing chronic allograft rejection (CREJ) after renal transplantation [Abstract 1135]. J Am Soc Nephrol 1995; 6(3): 1104.
19. Massy ZA, Guijarro C, Kasiske BL. Clinical predictors of chronic renal allograft rejection. Kidney Int 1995; 52: S85.
20. Hunsicker LG, Bennett LE. Design of trials to reduce late renal allograft loss: the price of success. Kidney Int 1995; 48: S120.
21. Rutten FFH, Ploeg RJ, McDonnell J. Kidney preservation with University of Wisconsin or Euro-Collins solution? An economic analysis. Transplant Proc 1993; 25 (1 Pt 2): 1586.
22. Lim EC, Terasaki PI. Early graft function. In: Terasaki P, ed. Clinical transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory, 401.
23. Troppmann C, Gillingham KJ, Gruessner RWG, et al. Delayed graft function in the absence of rejection has no long-term impact: a study of cadaver kidney recipients with good graft function at one year after transplantation. Transplantation 1996; 61: 1331.